Community protocol · Selank + Semax
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: SK + XA · Selank/Semax blend
Sources checked: 27 August 2026
This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Quick context
Linked in communities to stress and cognition claims; clinical benefit and safety of the blend are unproven.
This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.
Amounts, timing and cycles
This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.
Different amounts circulate online; no regulator-confirmed safe or effective dose exists.
Profile evidence level: anecdotal.
Community claims about time of day, fasting windows or training intervals are not validated clinical standards.
No individual recommendation.
Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community sourceReconstitution and U-100 conversion
No responsible U-100 conversion can be made for blends or vaguely named products until each component amount, total volume and verified composition are unambiguous.
No responsible U-100 conversion can be made for blends or vaguely named products until each component amount, total volume and verified composition are unambiguous.
Mechanism and research questions
Selank + Semax is classified as “Non-standardised blend of two experimental neuropeptides”. Linked in communities to stress and cognition claims; clinical benefit and safety of the blend are unproven. This describes the investigated pathway but does not validate a community use, amount, route or combination.
This studies how two individually experimental peptides acting on the nervous system are marketed together by vendors, similar to combining two separate tools into a set without testing them together. Studies mostly look at the individual substances, not the combination.
This studies how a peptide affects stress and anxiety responses in animal models, similar to observing whether an animal stays calmer in an unfamiliar environment. Behavioural tests and stress hormone levels are measured.
This examines whether a substance can protect nerve cells from stress or damage, such as after oxygen deprivation in a cell model. Cell survival and signalling markers in nerve tissue under lab conditions are measured.
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
Users exchange self-assembled combinations of several peptides and compare perceived effects, often without the specific combination ever having been studied. Such stack recommendations are personal opinions, not vetted protocols.
Subjective effects on concentration, mood, or stress perception after taking experimental neuropeptides are discussed, often based on personal journals. Such self-reported impressions are strongly influenced by expectation and do not replace controlled studies.
Vendors often advertise products with broad efficacy claims, comparison tables against competitors, and customer quotes. Such marketing statements are driven by sales interest and do not constitute independent scientific proof of efficacy.
Adverse effects and risk boundaries
Exclusion groups and professional assessment
Monitoring and laboratory markers
Evidence boundary
Clinical benefit and safety of the blend are unproven.
Published evidence
Claims rely mostly on personal experience reports and vendor statements rather than controlled studies.
This combination pairs two individually experimental neuropeptides; the blend is additionally not standardised.
Storage and stability
Troubleshooting and error sources
Regulatory status and WADA
No FDA- or EMA-approved medicinal product; efficacy and safety are not established.
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
Frequently asked questions
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
